<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Iron chelation therapy is often used to treat <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients requiring transfusion of red blood cells (RBC) </plain></SENT>
<SENT sid="1" pm="."><plain>A 76-year-old man with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> type refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, intermediate-1 IPSS risk, was referred when he became transfusion dependent </plain></SENT>
<SENT sid="2" pm="."><plain>He declined infusional chelation but subsequently accepted oral therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Following the initiation of chelation, RBC transfusion requirement ceased and he remained transfusion independent over 40 months later </plain></SENT>
<SENT sid="4" pm="."><plain>Over the same time course, ferritin levels decreased but did not normalize </plain></SENT>
<SENT sid="5" pm="."><plain>There have been eighteen other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients reported showing improvement in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level with iron chelation; nine became transfusion independent, nine had decreased transfusion requirements, and some showed improved trilineage myelopoiesis </plain></SENT>
<SENT sid="6" pm="."><plain>The clinical features of these patients are summarized and possible mechanisms for such an effect of iron chelation on cytopenias are discussed </plain></SENT>
</text></document>